Pennsylvanian medical school scientists at the University of Pennsylvania identified nine potential new treatments to COVID-19, including three, which are already approved by the management oversight of food quality and medicines (FDA) for the treatment of other diseases. This is reported in an article published in the Cell Reports magazine. Briefly about scientific work is described in a press release on MedicalXpress.
The researchers team checked thousands of existing drugs and connections to the ability to suppress the replication of the Coronavirus SARS-COV-2 causing COVID-19. Of the nine drugs that reduce the replication of SARS-COV-2 in the cells of the respiratory organs, three have already received approval for use: cyclosporine against a graft, Dakomitinib against cancer and salinomycin antibiotic. This will accelerate the tests of their effectiveness against coronavirus involving people.
In the United States, the only antiviral drugs from COVID-19, which received the resolution of the FDA for emergency use are Remidesivir and several antibody-based drugs, but they are expensive and not 100 percent effective.
The obtained evidence suggests that the virus uses a mechanism that can be broken, for example, hydroxychlorochin. However, in respiratory cells, the infection acts differently, which explains the absence of the effectiveness of this drug in clinical trials.